General Flashcards
What is the major disadvantage of clinical therapy involving drugs that act on ANS?
Lack of specificity
Parasympathetics control…
cardiac and smooth muscle
gland cells
nerve terminals
Parasympathetic presynaptic
nicotinic cholinergic
Parasympathetic postsynaptic
muscarinic cholinergic
Sympathetic (sweat glands) postsynaptic
muscarinic cholinergic
postsynaptic motor neurons
nicotinic cholinergic
sympathetic (cardiac and smooth muscle, gland cells, nerve terminals) postsynaptic motor neurons
adrenergic (alpha and beta)
Sympathetic (renal vascular smooth muscle) postsynaptic motor neuron
dopamine receptor
Adrenal medulla
nicotinic cholinergic receptor
releases Epi, NE
Cholinergic receptor types
muscarinic
Nicotinic
muscarinic subtypes
M1, M3, M5…Gq coupled
M2, M4….Gi coupled
Gq coupled muscarinic receptors
M1
M3
M5
Gi coupled muscarinic receptors
M2
M4
Nicotinic subtypes
Nm (neuromuscular/muscle type)
Nn (neuronal, or ganglion type)
Adrenergic subtypes
alpha 1, alpha 2
beta 1, beta 2, [beta 3]
Dopamine receptor subtypes
D1-D5
Other receptors
for NANC transmitters
- -NO
- -vasoactive intestinal peptide
- -neuropeptide Y
5 key features of neurotransmitter function that provide targets for drug therapy?
Synthesis Storage Release Reuptake Degredation
If Synthesis and Storage blocked…
usually rate-limiting steps, so…
produce long-term effects, but not immediately effective
If release blocked…
Rapid action and effective
If reuptake blocked…
Increased synaptic neurotransmitter concentrations (selective or non-selective)
If metabolism blocked…
reversible or irreversible:
increases transmitter levels
If recognition is blocked…
Receptor antagonists and agonists…high specificity
Sympathomimetic
mimicks… effects of impulses conveyed by adrenergic postganglionic fibers